For someone who says he’s won the right to keep his job, Donald Trump sure isn’t acting like it. Rather than comforting a nation currently being ravaged by the coronavirus, Trump largely has gone silent.
Other than falsely claiming that Pfizer deliberately withheld news of its vaccine progress until after the election, Trump hasn’t uttered word one about the potential for ultimately getting control of the pandemic either through public health measures or with a vaccine.
Instead Trump appears to be filling his days with cable news, golf (both this past Saturday and Sunday) and Tweet screaming about the election. This morning, rather than cheering the news from Moderna that its vaccine has been shown to be almost 95 percent effective, Trump thought it was a better use of his time and thumbs to attack the manufacturer of ballot counting machines.
In the words of Associated Press White House correspondent Jonathan Lemire, “the fight has been abandoned.”
Appearing Monday morning on MSNBC’s “Morning Joe” Lemire said, “As the president has been solely focused on his re-election, failed re-election effort, he’s largely stopped his day job and that nowhere more striking than this, managing the coronavirus pandemic. As Dr. [Anthony] Fauci said he hasn’t attended a meeting, a task force briefing, in months and according to our reporting he’s not receiving regular updates anymore.
“He’s been largely shut off from the process, and where we are now as the nation deals with this terrible wave, and we are seeing states suffer record number of infections, there’s no real federal leadership at all,” Lemire added. “There’s a vacuum.”
On top of that Trump is refusing to allow his administration to cooperate with the transition team of President-elect Joe Biden. By stonewalling Biden’s people the president is actively slowing down what should be the federal government’s preparations for deploying coronavirus vaccines in the early weeks of the Biden administration.
Both Moderna and Pfizer are pursuing emergency use authorizations from the U.S. Food and Drug Administration, which would pave the way for mass distribution early in 2021.